

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

## Complete if Known

Application Number 10/566224  
Filing Date September 14, 2007  
First Named Inventor Martin HENDRIX, et al.  
Art Unit 1624  
Examiner Name Rao Deepak K.  
Attorney Docket Number 01-2118

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/S.M./		3,165,520	01-12-1955	Paul SCHMIDT, et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	Foreign Patent Document Country Code* - Number* - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/S.M./		CA 2 484 997 A1	04-22-2003	Bayer Cropscience AG		
/S.M./		CA 2 417 631 A1	01-29-2003	Bayer Aktiengesellschaft		
		<del>CA 2 408 000 A1</del>	<del>09-06-2002</del>	<del>Bayer Aktiengesellschaft</del>		
		<del>CA 2 426 194 A1</del>	<del>09-04-2004</del>	<del>Bayer Healthcare AG</del>		
		<del>CA 2 490 292 A1</del>	<del>04-01-2004</del>	<del>Bayer Healthcare AG</del>		
		<del>CA 2 496 208 A1</del>	<del>04-01-2004</del>	<del>Bayer Healthcare AG</del>		
		<del>CA 2 283 211 A1</del>	<del>09-17-1998</del>	<del>Bayer Aktiengesellschaft</del>		
		<del>CH 696 000</del>	<del>01-01-1966</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>CH 396 024</del>	<del>01-31-1966</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>CH 696 006</del>	<del>01-31-1966</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>CH 396 026</del>	<del>01-31-1966</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>CH 396 027</del>	<del>01-31-1966</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>DE 1 450 000</del>	<del>08-22-1963</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>DE 1 149 013</del>	<del>05-22-1963</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>DE 9 409 006</del>	<del>00-10-1974</del>	<del>Chemische Fabrik von Heyden GmbH</del>		
		<del>DE 1 156 415</del>	<del>10-31-1963</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>DE 101 66 240</del>	<del>06-08-2003</del>	<del>Bayer, AG</del>		
		<del>DE 1 147 234</del>	<del>04-18-1963</del>	<del>CIBA Aktiengesellschaft</del>		
		<del>EP 0 006 761 A2</del>	<del>04-06-2000</del>	<del>Pfizer Inc.</del>		
		<del>EP 0 006 761 A2</del>	<del>04-20-2000</del>	<del>Pfizer Inc.</del>		
		<del>GB 937,726</del>	<del>00-26-1963</del>	<del>CIBA Limited</del>		
		<del>GB 975,301</del>	<del>10-26-1904</del>	<del>CIBA Limited</del>		
*	/S.M./	WO 2004/018474 A1	03-04-2004	Bayer Healthcare AG		
		<del>WO 2004/022200 A2</del>	<del>04-01-2004</del>	<del>Bayer Healthcare AG</del>		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/S.M./		F. Josef van der STAAY, et al., "The novel selective PDE9 inhibitor BAY 73-6591 improves learning and memory in rodents", NEUROPHARMACOLOGY, 55 (2008) pp. 908-916	
/S.M./		U. EBERT, et al., "Scopolamine model of dementia: electroencephalogram findings and cognitive performance", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, (1998) 28, pp. 944-949	
/S.M./		Joe PRICKAERTS, et al., "Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effect of 7-nitroindazole and zaprinast", EUROPEAN JOURNAL OF PHARMACOLOGY 337 (1997) pp. 125-136	
/S.M./		F. Zaragoza DÖRWALD, "Side Reactions in Organic Synthesis", A GUIDE TO SUCCESSFUL SYTHESIS DESIGN, 2005, 4 pages <b>preface</b>	
/S.M./		Kenneth F. PODRAZA, "Reductive Cyclization of Ketoesters Utilizing Sodium Cyanoborohydride: Synthesis of $\gamma$ - and $\delta$ -Lactones" J. HETEROCYCLIC CHEM., 24, 193 (1987)	
/S.M./		Internet Article, "Amnesia", From Wikipedia, the free encyclopedia, 3 pages , downloaded 12/18/08 < file:///C:/DOCUME~1/jmurray/LOCALS~1/Temp/RRAV9XSH.htm>	
/S.M./		Reid JA, "Role of phosphodiesterase isoenzymes in the control of rennin secretion: effects of selective enzyme inhibitors", CURR PHARM DES, 1999, Sep. 5(9): 725-35 <b>abstract</b>	
/S.M./		Edwin J. WEEBER, et al., "Molecular Genetics of Human Cognition", MOLECULAR INVENTIONS, Vol. 2, Issue 6, October 2002, pps. 376-391	
		<del>International Search Report for International Application No. PCT/EP2004/004466 mailed September 17, 2004, 6 pages</del>	
		<del>International Search Report for International Application No. PCT/EP2004/004466 mailed July 14, 2004, 6 pages</del>	
		<del>International Search Report for International Application No. PCT/EP2004/004466 mailed November 25, 2004, 6 pages</del>	
		<del>International Search Report for International Application No. PCT/EP2004/004466 mailed December 16, 2004, 6 pages</del>	
		<del>International Search Report for International Application No. PCT/EP2004/004466 mailed October 27, 2004, 6 pages</del>	
		<del>International Search Report for International Application No. PCT/EP2004/004466 mailed May 19, 2005, 10 pages</del>	
		<del>Scott H. SCODERLING, et al., "Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 25, issued June 19, 1998, pgs. 15553-15558</del>	
		<del>Scott H. SCODERLING, et al., "Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions", CURRENT OPINION IN CELL BIOLOGY, 2000, 12:174-179</del>	
		<del>Giuseppe G. ANDRECCI, et al., "Expression of cAMP-specific Phosphodiesterase 9A mRNA in the Rat Brain", THE JOURNAL OF NEUROSCIENCE, November 15, 2001, 21(22); pgs. 9068-9076</del>	
		<del>G. G. SHEN, et al., "Potential Purine Antagonist VII: Synthesis of 6-Allyldeoxy-2,3,4-trimethyl-1,2,3,4-tetrahydri-2H-pyrimidin-2-one", POTENTIAL PURINE ANTAGONISTS, VII, Vol. 23, February 1958, pgs. 191-200</del>	
		<del>Lubomyr PRAWCZYN, et al., "Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A", PNAS, Vol. 97, No. 7, March 28, 2000, pgs. 3702-3707</del>	
		<del>Douglas A. FISHER, et al., "Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 25, issued June 19, 1998, pgs. 15559-15564</del>	
		<del>Douglas A. FISHER, et al., "Isolation and Characterization of PDE9A, a Novel Human cAMP-Specific Phosphodiesterase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 245, April 15, 1998, pgs. 570-577</del>	
		<del>Sharon H. FRANCAIS, et al., "Characterization of a Novel cGMP Binding Protein from Bat Lung", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 255, No. 2, Issue of January 25, 1980, pgs. 620-626</del>	
		<del>Kenneth F. PODRAZA, et al., "Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 274, No. 69, issued June 25, 1999, pgs. 18438-18445</del>	
		<del>Julius GIELEN, et al., "A novel approach to amides from esters", TETRAHEDRON LETTERS, 42, 2003, pgs. 440-421</del>	
		<del>Rudolf GOMPPER, et al., "Substituted ethylmethylcarbamoyl and related thiocarbonyl, CARBOXYLIC ACID DERIVATIVES, Vol. 95, 1952, pgs. 2861-2870</del>	

	<del>Patel S, Chakrabarti, et al., "Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cyclic GMP-Sepharose Chromatography", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 269, No. 2, Issue of June 15, 1988, pgs. 8133-8141</del>	
	<del>Mitchell-GMERCIN, et al., "Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene" (PDE9A) that maps to 21q22.3; alternative splicing of mRNA transcripts, genomic structure and sequence", HUM GENET (1998) 103:385-392</del>	
	<del>J. M. DEWMAN, et al., "Cloning and characterization of PDE7B, a cGMP-specific phosphodiesterase", PNAS, Vol. 97, No. 1, January 4, 2000, pgs. 472-476</del>	
	<del>Kate LOUGHRNEY, et al., "Isolation and characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3', 5'-Cyclic Nucleotide Phosphodiesterases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 2, Issue of January 12, 1996, pgs. 796-806</del>	
	<del>James G. HOEFNER, et al., "Primary Structure of Identified Human from the Visual Cortex of Postnatal Data", THE JOURNAL OF NEUROSCIENCE, Vol. 6, No. 10, pgs. 3044-3060</del>	
	<del>Kate LOUGHRNEY, et al., "Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3', 5'-cyclic nucleotide phosphodiesterase", GENE, 216 (1998), pgs. 139-147</del>	
	<del>Stefan LOUGHERY, "Cyclic nucleotide phosphodiesterase (PDE) superfamily - A new target for the development of specific therapeutic agents", PHARMACOLOGY &amp; THERAPEUTICS, 109 (2006), pgs. 366-398</del>	

\*Note; only structures were considered.

Examiner Signature	/Susanna Moore/	Date Considered	06/01/2009
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.